Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7177249

CCOc1ccc(PC(=O)c2c(C)cccc2Cl)c(OCC)c1.[Li]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.40
▸ ELANE P08246 2/20 0.40
▸ TRPM4 Q8TD43 1/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ MAPT P10636 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ GAA P10253 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ MCL1 Q07820 1/20 0.35
▸ NOTUM Q6P988 1/20 0.35
▸ FADS1 O60427 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177244 0.98 KDM4E (0.40) KDM4EELANETRPM4SMN1; SMN2MAPT
Lithium SCHEMBL7178065 0.94 KDM4E (0.45) KDM4EELANESMN1; SMN2MAPTALDH1A1
Lithium SCHEMBL7180665 0.92 KDM4E (0.45) KDM4ESMN1; SMN2MAPTALDH1A1GAA
SCHEMBL7178061 0.92 KDM4E (0.45) KDM4EELANESMN1; SMN2MAPTALDH1A1
SCHEMBL7180652 0.89 KDM4E (0.45) KDM4ESMN1; SMN2MAPTALDH1A1GAA
Lithium SCHEMBL7177035 0.89 KMT2A (0.39) ELANETRPM4MAPTALDH1A1KMT2A
Lithium SCHEMBL7177659 0.89 PPARG (0.39) ALDH1A1TDP1MCL1
Lithium SCHEMBL7189263 0.89 SMN1; SMN2 (0.46) KDM4EELANESMN1; SMN2MAPTALDH1A1
SCHEMBL7180724 0.88 MCL1 (0.39) KDM4ETRPM4SMN1; SMN2MAPTALDH1A1
Lithium SCHEMBL7177734 0.87 PLA2G4B (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KDM4E 3226/4885ELANE 4357/4885TRPM4 3654/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KDM4E 2651/4885ELANE 4460/4885TRPM4 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.